# Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

> **NCT00091832** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 255 (actual)

## Conditions studied

- Breast Cancer
- Metastases
- Bone Metastases in Subjects With Advanced Breast Cancer

## Interventions

- **BIOLOGICAL:** Denosumab
- **DRUG:** IV Bisphosphonates

## Key facts

- **NCT ID:** NCT00091832
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-11
- **Final completion:** 2006-10
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2014-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091832, "Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00091832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*